You are here

MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA189637-01
Agency Tracking Number: R41CA189637
Amount: $222,795.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BELMONT, MA 02478-3915
United States
DUNS: 79142619
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 489-9871
Business Contact
Phone: (617) 489-9871
Research Institution
Partners Research Management 101 Huntington Ave, Suite 300
BOSTON, MA 02199-7603
United States

 () -
 Domestic nonprofit research organization

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy (more than 80%) and the third most common cause of death from cancer worldwide. Contrast-enhanced multi-phase multi-detector CT (MDCT) is a routine imaging modality for patients diagnosed with hepatic malignancy. The change of tumor size measured on single-phase (mostly portal-venous phase) MDCT images is used routinely for assessment of tumor response to treatment. With the advent of targeted cancer therapies (such as antiangiogenic treatment) over the past decade, the clinical outcome in the treatment of advanced HCC has been significantly improved. However, because of the difference in the mechanisms of therapies, measurement of tumors treatedwith targeted therapy does not necessarily accurately represent the change in viable tumor size due to the presence of necrosis. Therefore, the assessment of tumor response using tumor size alone may inadequately evaluate the treatment response for t

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government